Abstract:In this study we exploit a large panel of gastric cancer (GC) cell lines and powerful (phospho)proteomic workflows to provide the most comprehensive characterization of the GC proteome to date. The data are used to generate novel subclassifications and we identify, and then validate through functional analyses and interrogation of publicly available data, kinase targets for broad or precision GC treatment. Different molecular classifications for gastric cancer (GC) have been proposed based on multi‐omics platforms with the long‐term goal of improved precision treatment. However, the GC (phospho)proteome remains incompletely characterized, particularly at the level of tyrosine phosphorylation. In addition, previous multiomics‐based stratification of patient cohorts has lacked identification of corresponding cell line models and comprehensive validation of broad or subgroup‐selective therapeutic targets. To address these knowledge gaps, we applied a reverse approach, undertaking the most comprehensive (phospho)proteomic analysis of GC cell lines to date and cross‐validating this using publicly available data. Mass spectrometry (MS)‐based (phospho)proteomic and tyrosine phosphorylation datasets were subjected to individual or integrated clustering to identify subgroups that were subsequently characterized in terms of enriched molecular processes and pathways. Significant congruence was detected between cell line proteomic and specific patient‐derived transcriptomic subclassifications. Many protein kinases exhibiting 'outlier' expression or phosphorylation in the cell line dataset exhibited genomic aberrations in patient samples and association with poor prognosis, with casein kinase I isoform delta/epsilon (CSNK1D/E) being experimentally validated as potential therapeutic targets. Src family kinases were predicted to be commonly hyperactivated in GC cell lines, consistent with broad sensitivity to the next‐generation Src inhibitor eCF506. In addition, phosphoproteomic and integrative clustering segregated the cell lines into two subtypes, with epithelial–mesenchyme transition (EMT) and proliferation‐associated processes enriched in one, designated the EMT subtype, and metabolic pathways, cell–cell junctions, and the immune response dominating the features of the other, designated the metabolism subtype. Application of kinase activity prediction algorithms and interrogation of gene dependency and drug sensitivity databases predicted that the mechanistic target of rapamycin kinase (mTOR) and dual specificity mitogen‐activated protein kinase kinase 2 (MAP2K2) represented potential therapeutic targets for the EMT and metabolism subtypes, respectively, and this was confirmed using selective inhibitors. Overall, our study provides novel, in‐depth insights into GC proteomics, kinomics, and molecular taxonomy and reveals potential therapeutic targets that could provide the basis for precision treatments.

Proteomic heterogeneity of the extracellular matrix identifies histologic subtype-specific fibroblast in gastric cancer

Proteomic Heterogeneity of the Extracellular Matrix Identifies Histologic Subtype-Specific Fibroblast in Gastric Cancer

Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response

Transcriptome Profiling of Patient-Derived Tumor Xenografts Suggests Novel Extracellular Matrix-Related Signatures for Gastric Cancer Prognosis Prediction

Progressive and Prognostic Performance of an Extracellular Matrix-Receptor Interaction Signature in Gastric Cancer

Expression of immunohistochemical markers according to histological type in patients with early gastric cancer

Single Cell and Bulk RNA Sequencing Identifies Tumor Microenvironment Subtypes and Chemoresistance-Related IGF1+ Cancer-Associated Fibroblast in Gastric Cancer

Differential Expression of COL6 Family is a Potential Tumor Marker for Predicting Gastric Cancer

Abstract 5142: Proteome-wide Analysis Identifies Three Subgroups of Diffuse-Type Gastric Cancer

Zinc Finger Protein CTCF Regulates Extracellular Matrix (ECM)-Related Gene Expression Associated With the Wnt Signaling Pathway in Gastric Cancer

Molecular and cellular heterogeneity of gastric cancer explained by methylation-driven key regulators

The Keratin 17/YAP/IL6 Axis Contributes to E-cadherin Loss and Aggressiveness of Diffuse Gastric Cancer

Single-Cell and Bulk RNA Sequencing Reveal Malignant Epithelial Cell Heterogeneity and Prognosis Signatures in Gastric Carcinoma

Unsupervised Hierarchical Clustering Identifies Immune Gene Subtypes in Gastric Cancer

Subtyping of gastric cancer based on basement membrane genes that stratifies the prognosis, immune infiltration and therapeutic response

Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer

Differential Extracellular Matrix Proteomic Signatures in Malignant and Benign Polyps from Appalachian Region Colon Cancer Patients

Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity

Extracellular Matrix Biomarkers in Colorectal Cancer

Extracellular Matrix-Related Hubs Genes Have Adverse Effects on Gastric Adenocarcinoma Prognosis Based on Bioinformatics Analysis

Abstract 277: Cancer-associated fibroblasts, educated by tumor cells, differentially facilitate cancer cell invasion in cell-line based human gastric tumoroids